Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021
(From left to right): Danielle Belardo, MD, Rafael Diaz, MD, and Christie Mitchell Ballantyne, MD, FAHA
AHA21
Trials’ results highlight the potential for fish oil to fight COVID-19 and MK-0616 to lower cholesterol
Nov 15th, 2021
(left to right): Jacqueline E. Tamis-Holland, MD, and Jane Armitage, FRCP, FFPH, OBE
AHA21
New drugs, indications in cardiovascular disease
Researchers present research regarding aspirin and dementia, early P2Y12 inhibitors, ticagrelor reversal agent and oral factor XIa.
Nov 15th, 2021